Towards an improved global understanding of treatment and outcomes in people with type 2 diabetes: Rationale and methods of the DISCOVER observational study program

Journal of Diabetes and its Complications

Volumn 31, Issue 7, 2017, Pages 1188-1196

  Ji, Linong ^a   Bonnet, Fabrice ^b   Charbonnel, Bernard ^c   Gomes, Marilia B ^d   Kosiborod, Mikhail ^e,f   Khunti, Kamlesh ^g   Nicolucci, Antonio ^h   Pocock, Stuart ⁱ   Rathmann, Wolfgang ^j   Shestakova, Marina V ^k,l   Shimomura, Iichiro ^m   Watada, Hirotaka ⁿ   Fenici, Peter ^o   Hammar, Niklas ^p,q   Hashigami, Kiyoshi ^o   Macaraeg, Greg ^o   Surmont, Filip ^o   Medina, Jesús ^o  

^a PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

^b RENNES UNIVERSITY HOSPITAL   (France)

^c UNIVERSITÉ DE NANTES   (France)

^d STATE UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^e SAINT LUKE S MID AMERICA HEART INSTITUTE   (United States)

^f UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^g UNIVERSITY OF LEICESTER   (United Kingdom)

^h Center for Outcomes Research and Clinical Epidemiology   (Italy)

ⁱ LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^j HEINRICH HEINE UNIVERSITY   (Germany)

^k ENDOCRINOLOGY RESEARCH CENTRE   (Russian Federation)

^l I M SECHENOV FIRST MOSCOW STATE MEDICAL UNIVERSITY   (Russian Federation)

^m OSAKA UNIVERSITY   (Japan)

ⁿ JUNTENDO UNIVERSITY   (Japan)

^o ASTRAZENECA   (United Kingdom)

^p ASTRAZENECA R AND D   (Sweden)

^q KAROLINSKA INSTITUTE   (Sweden)

more..

Author keywords

Longitudinal observational study; Outcomes; Real world evidence; Second line therapy; Treatment patterns; Type 2 diabetes

Indexed keywords

ANTIDIABETIC AGENT; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

ARTICLE; CLINICAL PRACTICE; DIABETIC HYPERTENSION; DIABETIC PATIENT; DISEASE CONTROL; FEMALE; FOLLOW UP; HEALTH CARE PERSONNEL; HEALTH CARE SYSTEM; HEALTH CARE UTILIZATION; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERCHOLESTEROLEMIA; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; PATIENT-REPORTED OUTCOME; PROSPECTIVE STUDY; RISK FACTOR; BLOOD; CHEMICALLY INDUCED; CLINICAL TRIAL; COMBINATION DRUG THERAPY; COMPLICATION; DIABETIC COMPLICATION; DRUG MONITORING; DRUG RESISTANCE; ELECTRONIC HEALTH RECORD; EVIDENCE BASED MEDICINE; GLOBAL HEALTH; HEALTH SERVICES RESEARCH; HYPERGLYCEMIA; HYPOGLYCEMIA; METHODOLOGY; MULTIMODALITY CANCER THERAPY; PATIENT SATISFACTION; TREATMENT OUTCOME;

COMBINED MODALITY THERAPY; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; DRUG MONITORING; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; ELECTRONIC HEALTH RECORDS; EVIDENCE-BASED MEDICINE; FEMALE; GLOBAL HEALTH; GLYCATED HEMOGLOBIN A; HEALTH SERVICES RESEARCH; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; LONGITUDINAL STUDIES; MALE; PATIENT SATISFACTION; PRACTICE PATTERNS, PHYSICIANS'; PROSPECTIVE STUDIES; RESEARCH DESIGN; TREATMENT OUTCOME;

EID: 85019140473     PISSN: 10568727     EISSN: 1873460X     Source Type: Journal    
DOI: 10.1016/j.jdiacomp.2017.03.011     Document Type: Article

References (43)

1. International Diabetes Federation, IDF Diabetes Atlas. 7th ed., 2015 [Available at: http://www.diabetesatlas.org/; Accessed 10 February 2017].
2. Boyle, J.P., Engelgau, M.M., Thompson, T.J., Goldschmid, M.G., Beckles, G.L., Timberlake, D.S., et al. Estimating prevalence of type 1 and type 2 diabetes in a population of African Americans with diabetes mellitus. Am J Epidemiol 149 (1999), 55–63.
3. Bruno, G., Runzo, C., Cavallo-Perin, P., Merletti, F., Rivetti, M., Pinach, S., et al. Incidence of type 1 and type 2 diabetes in adults aged 30-49 years: the population-based registry in the province of Turin, Italy. Diabetes Care 28 (2005), 2613–2619.
4. Evans, J.M., Newton, R.W., Ruta, D.A., MacDonald, T.M., Morris, A.D., Socio-economic status, obesity and prevalence of type 1 and type 2 diabetes mellitus. Diabet Med 17 (2000), 478–480.
5. Holman, N., Young, B., Gadsby, R., Current prevalence of type 1 and type 2 diabetes in adults and children in the UK. Diabet Med 32 (2015), 1119–1120.
6. Morrish, N.J., Wang, S.L., Stevens, L.K., Fuller, J.H., Keen, H., Mortality and causes of death in the WHO multinational study of vascular disease in diabetes. Diabetologia 44 (2001), S14–S21.
7. Preis, S.R., Pencina, M.J., Hwang, S.J., D'Agostino, R.B. Sr., Savage, P.J., Levy, D., et al. Trends in cardiovascular disease risk factors in individuals with and without diabetes mellitus in the Framingham heart study. Circulation 120 (2009), 212–220.
8. Chinese Diabetes Society, Chinese guideline for type 2 diabetes prevention (2013). Chinese J Diabetes 22 (2014), 2–42.
9. Garber, A.J., Abrahamson, M.J., Barzilay, J.I., Blonde, L., Bloomgarden, Z.T., Bush, M.A., et al. AACE/ACE comprehensive diabetes management algorithm 2015. Endocr Pract 21 (2015), 438–447.
10. International Diabetes Federation, Global Guideline for Type 2 Diabetes. Available at http://www.idf.org/sites/default/files/IDF-Guideline-for-Type-2-Diabetes.pdf, 2012 [Accessed November 2016, 30].
11. Inzucchi, S.E., Bergenstal, R.M., Buse, J.B., Diamant, M., Ferrannini, E., Nauck, M., et al. Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 58 (2015), 429–442.
12. Qaseem, A., Humphrey, L.L., Sweet, D.E., Starkey, M., Shekelle, P., Oral pharmacologic treatment of type 2 diabetes mellitus: a clinical practice guideline from the American College of Physicians. Ann Intern Med 156 (2012), 218–231.
13. Holman, R.R., Paul, S.K., Bethel, M.A., Matthews, D.R., Neil, H.A., 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359 (2008), 1577–1589.
14. Patel, A., MacMahon, S., Chalmers, J., Neal, B., Billot, L., Woodward, M., et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358 (2008), 2560–2572.
15. Ray, K.K., Seshasai, S.R., Wijesuriya, S., Sivakumaran, R., Nethercott, S., Preiss, D., et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet 373 (2009), 1765–1772.
16. Stratton, I.M., Adler, A.I., Neil, H.A., Matthews, D.R., Manley, S.E., Cull, C.A., et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321 (2000), 405–412.
17. UK Prospective Diabetes Study (UKPDS) Group, Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352 (1998), 837–853.
18. Marso, S.P., Daniels, G.H., Brown-Frandsen, K., Kristensen, P., Mann, J.F., Nauck, M.A., et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 375 (2016), 311–322.
19. Zinman, B., Wanner, C., Lachin, J.M., Fitchett, D., Bluhmki, E., Hantel, S., et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373 (2015), 2117–2128.
20. Ware, J.E., Kosinski, M., Bjorner, J.B., Turner-Bowker, D.M., Gandek, B., Maruish, M.E., User's Manual for the SF-36v2 Health Survey. 2007, QualityMetric Incorporated, Lincoln, RI.
21. Stargardt, T., Gonder-Frederick, L., Krobot, K.J., Alexander, C.M., Fear of hypoglycaemia: defining a minimum clinically important difference in patients with type 2 diabetes. Health Qual Life Outcomes, 7, 2009, 91.
22. Carlsson, A.C., Wandell, P.E., Gigante, B., Leander, K., Hellenius, M.L., de Faire, U., Seven modifiable lifestyle factors predict reduced risk for ischemic cardiovascular disease and all-cause mortality regardless of body mass index: a cohort study. Int J Cardiol 168 (2013), 946–952.
23. Ishi, H., Bradley, C., Riazi, A., Barendse, S., Yamamoyo, T., Tonyobyo ticho manzokudo sitsumonhyo (DTSQ) no nihongo honyaku to hyoka ni kansuru kenkyu [the Japanese version of the diabetes treatment satisfaction questionnaire (DSTQ): translation and clinical evaluation]. Igaku no Ayumi 1992 (2000), 809–814.
24. Kobayashi, S., Murakami, K., Sasaki, S., Okubo, H., Hirota, N., Notsu, A., et al. Comparison of relative validity of food group intakes estimated by comprehensive and brief-type self-administered diet history questionnaires against 16 d dietary records in Japanese adults. Public Health Nutr 14 (2011), 1200–1211.
25. Sasaki, S., Yanagibori, R., Amano, K., Self-administered diet history questionnaire developed for health education: a relative validation of the test-version by comparison with 3-day diet record in women. J Epilepsy 8 (1998), 203–215.
26. Craig, C.L., Marshall, A.L., Sjostrom, M., Bauman, A.E., Booth, M.L., Ainsworth, B.E., et al. International physical activity questionnaire: 12-country reliability and validity. Med Sci Sports Exerc 35 (2003), 1381–1395.
27. Murase, N., Katsumura, T., Ueda, C., Inoue, S., Shimomitsu, T., Validity and reliability of Japanese version of international physical activity questionnaire. J Health Welf Stat 49 (2002), 1–9.
28. Bradley, C., de Pablos-Velasco, P., Parhofer, K.G., Eschwege, E., Gonder-Frederick, L., Simon, D., PANORAMA: a European study to evaluate quality of life and treatment satisfaction in patients with type-2 diabetes mellitus — study design. Prim Care Diabetes 5 (2011), 231–239.
29. Echtay, A., Tsur, A., Hasan, M.I., Abu-Hijleh, M.O., Al Khatib, N., Andari, E., et al. Clinical experience with insulin detemir in patients with type 2 diabetes from the near east countries. Diabetes Ther 4 (2013), 399–408.
30. Freemantle, N., Balkau, B., Danchin, N., Wang, E., Marre, M., Vespasiani, G., et al. Factors influencing initial choice of insulin therapy in a large international non-interventional study of people with type 2 diabetes. Diabetes Obes Metab 14 (2012), 901–909.
31. Khunti, K., Caputo, S., Damci, T., Dzida, G.J., Ji, Q., Kaiser, M., et al. The safety and efficacy of adding once-daily insulin detemir to oral hypoglycaemic agents in patients with type 2 diabetes in a clinical practice setting in 10 countries. Diabetes Obes Metab 14 (2012), 1129–1136.
32. Kim, C.H., Han, K.A., Oh, H.J., Tan, K.E., Sothiratnam, R., Tjokroprawiro, A., et al. Safety, tolerability, and efficacy of metformin extended-release oral antidiabetic therapy in patients with type 2 diabetes: an observational trial in Asia. J Diabetes 4 (2012), 395–406.
33. Li, C., Hung, Y.J., Qamruddin, K., Aziz, M.F., Stein, H., Schmidt, B., International noninterventional study of acarbose treatment in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract 92 (2011), 57–64.
34. Liebl, A., Jones, S., Goday, A., Benroubi, M., Castell, C., Haupt, A., et al. Clinical outcomes after insulin initiation in patients with type 2 diabetes: 24-month results from INSTIGATE. Diabetes Ther, 3, 2012, 9.
35. Mathieu, C., Barnett, A.H., Brath, H., Conget, I., de Castro, J.J., Goke, R., et al. Effectiveness and tolerability of second-line therapy with vildagliptin vs. other oral agents in type 2 diabetes: a real-life worldwide observational study (EDGE). Int J Clin Pract 67 (2013), 947–956.
36. Matthaei, S., Reaney, M., Mathieu, C., Ostenson, C.G., Krarup, T., Guerci, B., et al. Patients with type 2 diabetes initiating exenatide twice daily or insulin in clinical practice: CHOICE study. Diabetes Ther, 3, 2012, 6.
37. Oguz, A., Benroubi, M., Brismar, K., Melo, P., Morar, C., Cleall, S.P., et al. Clinical outcomes after 24 months of insulin therapy in patients with type 2 diabetes in five countries: results from the TREAT study. Curr Med Res Opin 29 (2013), 911–920.
38. Rosales, R., Abou Jaoude, E., Al-Arouj, M., Fawwad, A., Orabi, A., Shah, P., et al. Clinical effectiveness and safety of vildagliptin in > 19 000 patients with type 2 diabetes: the GUARD study. Diabetes Obes Metab 17 (2015), 603–607.
39. Shah, S.N., Litwak, L., Haddad, J., Chakkarwar, P.N., Hajjaji, I., The A1chieve study: a 60 000-person, global, prospective, observational study of basal, meal-time, and biphasic insulin analogs in daily clinical practice. Diabetes Res Clin Pract 88 (2010), S11–S16.
40. Tsai, S.T., Pathan, F., Ji, L., Yeung, V.T., Chadha, M., Suastika, K., et al. First insulinization with basal insulin in patients with type 2 diabetes in a real-world setting in Asia. J Diabetes 3 (2011), 208–216.
41. Valensi, P., Benroubi, M., Borzi, V., Gumprecht, J., Kawamori, R., Shaban, J., et al. The IMPROVE study — a multinational, observational study in type 2 diabetes: baseline characteristics from eight national cohorts. Int J Clin Pract 62 (2008), 1809–1819.
42. Vichayanrat, A., Matawaran, B.J., Wibudi, A., Ferdous, H.S., Aamir, A.H., Aggarwal, S.K., et al. Assessment of baseline characteristics, glycemic control and oral antidiabetic treatment in Asian patients with diabetes: the registry for assessing OAD usage in diabetes management (REASON) Asia study. J Diabetes 5 (2013), 309–318.
43. Arnold, S.V., Inzucchi, S.E., McGuire, D.K., Mehta, S.N., Goyal, A., Sperling, L.S., et al. Evaluating the quality of comprehensive cardiometabolic care for patients with type 2 diabetes in the U.S.: the diabetes collaborative registry. Diabetes Care 39 (2016), e99–e101.